Rather, the activation of the Wnt/β-catenin pathway by the addition of WNT3A or R-spondin1 is a prerequisite for the long-term expansion of SCLC tumor organoids, in combination with ALK receptor and BMP signaling inhibition. The gene discussed is WNT3A; the disease is neoplasm.